Wandercraft Raises $75M in Series D to Power Global Growth of AI Robotics

📅 Date & Amount

• On June 11, 2025, Wandercraft announced it secured $75 million in combined equity and debt via its Series D funding round.

🔹 Key Investors & Strategic Backers

• Led by a mix of investors including Renault Group, the PSIM Fund (through Bpifrance and France’s France 2030 program), Quadrant Management, Teampact Ventures, LBO France, Mutuelles Impact (XAnge), Cemag Invest, Martagon Capital, and AG2R LA MONDIALE.
• Renault Group has also taken a minority stake and entered a strategic manufacturing partnership, leveraging its industrial scale to help mass-produce Wandercraft’s robotic solutions.

🎯 What the Funding Will Support

1. Eve – The world’s first self-balancing personal exoskeleton, now in clinical trials, projected to reach the consumer market by 2026, for personal mobility in home and outdoor environments.
2. Atalante X – An established rehabilitation exoskeleton already deployed in over 100 hospitals worldwide, with FDA clearance and substantial clinical trial momentum.
3. Calvin‑40 – A humanoid industrial robot developed in just 40 days, showcasing Wandercraft’s rapid‐build platform, aimed at physically demanding tasks on factory floors.

📈 Impressive Traction & Milestones

• Since its $45M Series C, Wandercraft achieved a 10× revenue increase, expanded U.S. operations, and grew its Atalante X footprint globally.
• The Atalante X system has garnered two FDA clearances, participated in 20+ clinical studies, aided over 2,500 users, and logged more than 14 million steps.
• Launched the “Walk in New York by Wandercraft” center at NYC’s Cure® healthcare campus—a clinical and commercial base ahead of Eve’s U.S. debut.

🥇 Recognition & Industry Honors

• Showcased at the 2024 Olympic and Paralympic Torch Relay, CES 2025, and NVIDIA GTC.
• Winner of a 2025 SXSW Innovation Award in AI.
• Included in France’s prestigious FT120 startup index.

🏭 Renault Partnership Highlights

• Renault brings veteran expertise in industrial-scale manufacturing, cost optimization, and robotics integration for automotive and factory workflows.
• The Calvin line is intended to reduce worker strain and boost productivity in Renault’s own plants, eventually standardizing exoskeleton production.

🌍 The Broader Impact

This infusion positions Wandercraft to evolve from a clinical rehabilitation innovator into a multi-faceted robotics leader, spanning:

• Personal mobility (Eve) – Empowering users to walk hands-free in daily life.
• Rehabilitation (Atalante X) – Enhancing physical therapy in clinics worldwide.
• Industrial robotics (Calvin series) – Automating physically demanding tasks and improving workplace safety.

Thanks to AI-driven self-balancing and neural control technology, Wandercraft’s systems have been rigorously tested—receiving FDA nods and being deployed across continents, while also forging critical manufacturing alliances.

📌 Outlook & Key Dates

In summary, Wandercraft’s Series D round marks a pivotal step toward transforming robotic mobility—from clinics to homes to factories. Bolstered by strategic investors like Renault and the French government, supported by rich clinical validation and commercial partnerships, Wandercraft appears well on track to redefine how people move and work with AI-powered robotics.

Source: https://www.wandercraft.eu/articles/wandercraft-announces-series-d-round-bringing-75m-in-total-funding-secured-for-global-acceleration-of-ai-powered-robotics